{"DataElement":{"publicId":"7171858","version":"2","preferredName":"Patient Prior Cytotoxic Chemotherapy Metastatic Breast Carcinoma Occurrence Confirmation Clinical Trial Eligibility Criteria Status","preferredDefinition":"The status of patient eligibility verification for the requirements of cytotoxic chemotherapy for metastatic breast cancer as outlined in the study protocol.","longName":"ELIG_PRR_CYCHEMO_CONF","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"7169605","version":"1","preferredName":"Patient Prior Cytotoxic Chemotherapy Metastatic Breast Carcinoma Occurrence Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Earlier in time or order._A drug therapy that is used to destroy cancer cells._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._An instance of something happening, such as an event or incident._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2177068v1.0:7170159v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7170159","version":"1","preferredName":"Prior Cytotoxic Chemotherapy Metastatic Breast Carcinoma Occurrence Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:Anticancer drugs that kill cells, especially cancer cells.:A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:An instance of something happening, such as an event or incident.:Having been established or verified.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"7170159v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cytotoxic Chemotherapy","conceptCode":"C15681","definition":"A drug therapy that is used to destroy cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8F8B00-A795-57FA-E053-F662850A2A32","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8C6503-0EA1-7369-E053-F662850A3086","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-14","modifiedBy":"TAYLORT","dateModified":"2020-02-26","changeDescription":"2/14/20 EA1183/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5676955","version":"2","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified._A condition or state at a particular time.","longName":"CONFSTAT","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"11","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unconfirmed","valueDescription":"Negation Confirmation","ValueMeaning":{"publicId":"5676956","version":"1","preferredName":"Negation Confirmation","longName":"5676956","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49380D88-AB51-745A-E053-F662850AA135","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE40-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"Confirmed","valueDescription":"Confirmation","ValueMeaning":{"publicId":"3953314","version":"1","preferredName":"Confirmation","longName":"3953314","preferredDefinition":"Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A874-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-11-18","modifiedBy":"TSESU","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE4A-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE54-165A-E053-4EBD850AA952","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7329879","version":"1","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified.:A condition or state at a particular time.","longName":"C25458:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE19-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE2A-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/10/20 tmt versioned to 2.0 for changes to Long and Short names.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient has not received grea","type":"Preferred Question Text","description":"Patient has not received greater than 3 lines of cytotoxic chemotherapy for metastatic breast cancer.","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D42BBC-5566-5666-E053-4EBD850A46C7","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-11","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/11/20 CDE versioned for updated VD; tmt. 2/26/20 tmt released.; 2/17/20 EA1183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}